![](/img/cover-not-exists.png)
Preclinical and first-in human development of SGM-1019, a first-in-class novel small molecule modulator of inflammasome activity for the treatment of nonalcoholic steatohepatitis (NASH)
Dabbagh, K., Steven Dodson, G., Yamamoto, L., Baeza-Raja, B., Goodyear, A.W.Volume:
68
Language:
english
Journal:
Journal of Hepatology
DOI:
10.1016/S0168-8278(18)30341-6
Date:
April, 2018
File:
PDF, 50 KB
english, 2018